If you remember within 12 hours of the next dose, skip the missed tablet and continue with your regular weekly schedule. Do not double-dose, as this can increase the risk of gastrointestinal irritation.
Alendronate should be taken at least 30 minutes before any calcium, antacid, or iron supplement. Taking them together can markedly reduce the absorption of alendronate.
Remaining upright helps the tablet travel quickly to the stomach, minimizing contact with the oesophagus, which reduces the risk of irritation or ulceration.
Mild to moderate renal impairment (eGFR 30-50 mL/min) may be acceptable, but dosing should be guided by a clinician who will monitor kidney function regularly. Severe impairment (eGFR < 30) is a contraindication.
Significant increases in BMD are typically observed after 6 to 12 months of consistent weekly dosing, though fracture risk reduction may become evident after 2 years.
Alendronate is not recommended during pregnancy or while breastfeeding. Women of child-bearing potential should discuss alternative osteoporosis strategies with their doctor.
Persistent thigh or groin pain, especially if it worsens with activity, may signal an impending atypical fracture. Prompt medical evaluation, including imaging, is essential.
Invasive dental work (e.g., extractions) can raise the risk of ONJ, particularly after prolonged bisphosphonate use. It is advisable to complete necessary dental treatment before starting alendronate, and maintain excellent oral hygiene.
Adequate vitamin D levels are crucial for optimal calcium absorption and bone health. Most clinicians recommend a daily supplement of 800-1000 IU vitamin D alongside alendronate therapy.
Yes, but carry the original prescription label and a copy of the prescribing doctor’s note. Some countries may require additional documentation; checking local regulations before travel is prudent.
Alendronate (active ingredient: alendronic acid) belongs to the bisphosphonate class of medicines, which are used to strengthen bone and reduce the risk of fractures. It is available in the United Kingdom as a prescription-only pill in two strengths: 35 mg and 70 mg, typically taken once weekly. The drug is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).
Alendronate binds tightly to hydroxyapatite crystals in bone, especially at sites where bone is being remodeled. When osteoclasts-cells that break down bone-attach to the alendronate-coated surface, the drug is internalised and disrupts the mevalonate pathway, which is essential for osteoclast function. This inhibition leads to reduced bone resorption, allowing osteoblasts (bone-building cells) to gradually increase bone density.
Key pharmacologic points:
Alendronate is approved by the MHRA for the following indications:
The medication is intended for adults with confirmed low bone density (T-score ≤ -2.5) or for those with a history of fragility fractures.
Some clinical studies have explored alendronate for conditions such as:
Disclaimer: Off-label use of alendronate must be overseen by a qualified healthcare professional, with careful risk-benefit assessment.
Standard dosing: 70 mg once weekly for osteoporosis; 35 mg once weekly for prevention or for Paget’s disease, as prescribed.
Administration steps:
Swallow a whole tablet with at least 200 mL of plain water.
Do not chew, crush, or split the pill.
Remain seated or standing upright for a minimum of 30 minutes before lying down, eating, or drinking anything else.
Missed dose: If a dose is forgotten, take it as soon as remembered unless it is within 12 hours of the next scheduled dose; in that case, skip the missed tablet and resume the regular schedule. Doubling a dose is never advised.
Overdose: Signs may include severe abdominal pain, vomiting, and electrolyte disturbances. Immediate medical attention is required; supportive care is the mainstay of treatment.
Discontinuation: Stopping alendronate abruptly may lead to a rapid rise in bone turnover. A gradual taper is not usually required, but clinicians often reassess fracture risk after 3-5 years of therapy and consider a drug holiday if appropriate.
This article provides educational information about alendronate and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
